Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Ptc Therapeutics (PTCT)
Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 26.28 (+1.58%)
Why PTC Therapeutics Soared 15% Higher Today

The company scored a $1 billion upfront payment for expanding a commercial partnership.

PTCT : 26.28 (+1.58%)
RPRX : 28.77 (+0.03%)
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023...

PTCT : 26.28 (+1.58%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...

PTCT : 26.28 (+1.58%)
PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio...

PTCT : 26.28 (+1.58%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors...

PTCT : 26.28 (+1.58%)
CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

PTCT : 26.28 (+1.58%)
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the two recipients of its 2023 STRIVE Awards for Duchenne Muscular Dystrophy. Through the...

PTCT : 26.28 (+1.58%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Citi 2023...

PTCT : 26.28 (+1.58%)
PTC Therapeutics: Q2 Earnings Snapshot

PTC Therapeutics: Q2 Earnings Snapshot

PTCT : 26.28 (+1.58%)

Barchart Exclusives

2 Beaten-Down Growth Stocks With 90% or More Upside Potential in 2024
While these stocks have taken a beating this year, Wall Street believes they have major rebound potential in 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar